December 15, 2020
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ — IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on...
LUNDBECK FOUNDATION AWARDS GRANTS WORTH DKK 57 MILLION TO BOLD PROJECTS WITH THE POTENTIAL TO PRODUCE NEW KNOWLEDGE IN THE FIELD OF NEUROSCIENCE The brains behind the projects are 29 researchers associated with universities and hospitals in Denmark. They are being funded by the Lundbeck Foundation LF Experiments research programme.   (The 29 researchers who...
€5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares BYFAVO expected to be launched in the United States within the coming weeks This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15...


The Lundbeck Foundation increases its commitment to IO Biotech
12. January 2021
The Lundbeck Foundation launches 2030 strategy with ambitious goals for grant and commercial activities
22. December 2020
Lundbeck foundation awards grants worth dkk 57 million to bold projects
15. December 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge